Literature DB >> 26304989

Interaction of Macrophage Antigen 1 and CD40 Ligand Leads to IL-12 Production and Resistance in CD40-Deficient Mice Infected with Leishmania major.

Ifeoma Okwor1, Ping Jia2, Jude E Uzonna3.   

Abstract

Although some studies indicate that the interaction of CD40 and CD40L is critical for IL-12 production and resistance to cutaneous leishmaniasis, others suggest that this pathway may be dispensable. In this article, we compared the outcome of Leishmania major infection in both CD40- and CD40L-deficient mice after treatment with rIL-12. We show that although CD40 and CD40L knockout (KO) mice are highly susceptible to L. major, treatment with rIL-12 during the first 2 wk of infection causes resolution of cutaneous lesions and control of parasite replication. Interestingly, although treated CD40 KO mice remained healed, developed long-term immunity, and were resistant to secondary L. major challenge, treated CD40L KO reactivated their lesion after cessation of rIL-12 treatment. Disease reactivation in CD40L KO mice was associated with impaired IL-12 and IFN-γ production and a concomitant increase in IL-4 production by cells from lymph nodes draining the infection site. We show that IL-12 production by dendritic cells and macrophages via CD40L-macrophage Ag 1 (Mac-1) interaction is responsible for the sustained resistance in CD40 KO mice after cessation of rIL-12 treatment. Blockade of CD40L-Mac-1 interaction with anti-Mac-1 mAb led to spontaneous disease reactivation in healed CD40 KO mice, which was associated with impaired IFN-γ response and loss of infection-induced immunity after secondary L. major challenge. Collectively, our data reveal a novel role of CD40L-Mac-1 interaction in IL-12 production, development, and maintenance of optimal Th1 immunity in mice infected with L. major.
Copyright © 2015 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26304989     DOI: 10.4049/jimmunol.1500922

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  7 in total

Review 1.  Cytokines and Signaling Networks Regulating Disease Outcomes in Leishmaniasis.

Authors:  Amrita Saha; Souravi Roy; Anindita Ukil
Journal:  Infect Immun       Date:  2022-07-11       Impact factor: 3.609

Review 2.  Novel Functions of Integrins as Receptors of CD154: Their Role in Inflammation and Apoptosis.

Authors:  Ghada S Hassan; Suzanne Salti; Walid Mourad
Journal:  Cells       Date:  2022-05-25       Impact factor: 7.666

Review 3.  T Cell Cosignaling Molecules in Transplantation.

Authors:  Mandy L Ford
Journal:  Immunity       Date:  2016-05-17       Impact factor: 31.745

4.  Frontline Science: CD40 signaling restricts RNA virus replication in Mϕs, leading to rapid innate immune control of acute virus infection.

Authors:  Kai J Rogers; Olena Shtanko; Laura L Stunz; Laura N Mallinger; Tina Arkee; Megan E Schmidt; Dana Bohan; Bethany Brunton; Judith M White; Steve M Varga; Noah S Butler; Gail A Bishop; Wendy Maury
Journal:  J Leukoc Biol       Date:  2020-05-22       Impact factor: 4.962

5.  miR-21 Expression Determines the Early Vaccine Immunity Induced by LdCen -/- Immunization.

Authors:  Sreenivas Gannavaram; Parna Bhattacharya; Abid Siddiqui; Nevien Ismail; Subha Madhavan; Hira L Nakhasi
Journal:  Front Immunol       Date:  2019-09-24       Impact factor: 7.561

6.  CD40 Generation 2.5 Antisense Oligonucleotide Treatment Attenuates Doxorubicin-induced Nephropathy and Kidney Inflammation.

Authors:  Aaron J Donner; Steve T Yeh; Gene Hung; Mark J Graham; Rosanne M Crooke; Adam E Mullick
Journal:  Mol Ther Nucleic Acids       Date:  2015-12-01       Impact factor: 10.183

7.  Impact of intrarectal chromofungin treatment on dendritic cells-related markers in different immune compartments in colonic inflammatory conditions.

Authors:  Kunal Kapoor; Nour Eissa; Diane Tshikudi; Charles N Bernstein; Jean-Eric Ghia
Journal:  World J Gastroenterol       Date:  2021-12-21       Impact factor: 5.742

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.